These results support a model in which SF3B1 mutation drives LOY as part of the clonal evolution of CLL, affecting CLL pathogenesis by interfering with both CLL intrinsic processes and inducing T-cell dysregulation. Here, SF3B1 is linked to B-cell chronic lymphocytic leukemia.